Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18458318 | 0.92 | IDH2 (1.00) | IDH2 | |
| SCHEMBL20210806 | 0.92 | IDH2 (0.85) | IDH2 | |
| SCHEMBL18458303 | 0.90 | IDH2 (0.86) | IDH2 | |
| SCHEMBL18458138 | 0.89 | IDH2 (0.83) | IDH2 | |
| SCHEMBL18458151 | 0.84 | IDH2 (1.00) | IDH2 | |
| SCHEMBL18458316 | 0.83 | IDH2 (1.00) | IDH2 | |
| SCHEMBL18458056 | 0.83 | IDH2 (1.00) | IDH2 | |
| SCHEMBL15702503 | 0.83 | IDH2 (0.86) | IDH2 | |
| SCHEMBL28444177 | 0.82 | IDH2 (0.74) | IDH2 | |
| SCHEMBL20210798 | 0.82 | IDH2 (0.72) | IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3330263-B1 | PHENYLUREA DERIVATIVES AS ISOCITRATE DEHYDROGENASE 2 INHIBITORS FOR TREATING CANCER | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2020-11-18 | — | — | EP | disclosed |
| EP-3330263-B1 | PHENYLUREA DERIVATIVES AS ISOCITRATE DEHYDROGENASE 2 INHIBITORS FOR TREATING CANCER | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2020-11-18 | — | — | EP | disclosed |
| CN-107922375-B | Anti-tumor compounds targeting the IDH2 mutation and methods of use thereof | 正大天晴药业集团股份有限公司 | 2020-05-22 | — | — | CN | disclosed |
| US-10155722-B2 | Antitumor compound targeting IDH2 mutation and method of use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-12-18 | — | — | US | disclosed |
| US-20180222853-A1 | ANTITUMOR COMPOUND TARGETING IDH2 MUTATION AND METHOD OF USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-08-09 | — | — | US | disclosed |
| US-20180222853-A1 | ANTITUMOR COMPOUND TARGETING IDH2 MUTATION AND METHOD OF USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-08-09 | — | — | US | disclosed |
| EP-3330263-A1 | ANTITUMOR COMPOUND TARGETING IDH2 MUTATION AND METHOD OF USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-06-06 | — | — | EP | disclosed |
| EP-3330263-A1 | ANTITUMOR COMPOUND TARGETING IDH2 MUTATION AND METHOD OF USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017016523-A1 | ANTITUMOR COMPOUND TARGETING IDH2 MUTATION AND METHOD OF USE THEREOF | 正大天晴药业集团股份有限公司 | 2017-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155722-B2 | Antitumor compound targeting IDH2 mutation and method of use thereof | IDH2, IDH3A, IDH1 | IDH2 1/4885 |
| US-20180222853-A1 | ANTITUMOR COMPOUND TARGETING IDH2 MUTATION AND METHOD OF USE THEREOF | IDH2, IDH3A, IDH1 | IDH2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.